Post-earnings recap
Reported
Mon, May 12, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing EPS expectations, TG Therapeutics saw a positive stock reaction, rising 5.02%. This increase may reflect investor confidence in the company's long-term strategy and pipeline developments. The lack of revenue data and guidance suggests uncertainty, but management's optimistic tone may have reassured some investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.25 | N/A | -19.05% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism about future developments. They highlighted their focus on long-term goals.
Management acknowledged the challenges faced in the quarter but expressed confidence in their ongoing projects.
They emphasized their commitment to advancing their pipeline despite the EPS miss.